Search results
Showing 1711 to 1725 of 8212 results
Awaiting development Reference number: GID-TA10685 Expected publication date: TBC
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Awaiting development Reference number: GID-TA10715 Expected publication date: TBC
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Awaiting development Reference number: GID-TA10716 Expected publication date: TBC
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Awaiting development Reference number: GID-TA10717 Expected publication date: TBC
Awaiting development Reference number: GID-TA10721 Expected publication date: TBC
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development Reference number: GID-TA10723 Expected publication date: TBC
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Awaiting development Reference number: GID-TA10773 Expected publication date: TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Awaiting development Reference number: GID-TA10774 Expected publication date: TBC
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Awaiting development Reference number: GID-TA10776 Expected publication date: TBC
Awaiting development Reference number: GID-TA10787 Expected publication date: TBC
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Awaiting development Reference number: GID-TA10823 Expected publication date: TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
In development Reference number: GID-TA11186 Expected publication date: TBC